EMERGENT BIOSOLUTIONS INC.: operating lease right-of-use asset

What this measure means

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Exact concept: us-gaap:OperatingLeaseRightOfUseAsset. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2021-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• EMERGENT BIOSOLUTIONS INC.: total assets
• EMERGENT BIOSOLUTIONS INC.: total liabilities
• EMERGENT BIOSOLUTIONS INC.: stockholders equity
• EMERGENT BIOSOLUTIONS INC.: cash and cash equivalents
• EMERGENT BIOSOLUTIONS INC.: net income or loss
• EMERGENT BIOSOLUTIONS INC.: operating cash flow
• EMERGENT BIOSOLUTIONS INC.: capital expenditure payments
• EMERGENT BIOSOLUTIONS INC.: revenue
• EMERGENT BIOSOLUTIONS INC.: contract revenue excluding tax
• EMERGENT BIOSOLUTIONS INC.: financing cash flow
• EMERGENT BIOSOLUTIONS INC.: investing cash flow
• EMERGENT BIOSOLUTIONS INC.: retained earnings or deficit
• EMERGENT BIOSOLUTIONS INC.: basic weighted-average shares
• EMERGENT BIOSOLUTIONS INC.: diluted weighted-average shares
• EMERGENT BIOSOLUTIONS INC.: basic earnings per share
• EMERGENT BIOSOLUTIONS INC.: diluted earnings per share
• EMERGENT BIOSOLUTIONS INC.: income tax expense or benefit
• EMERGENT BIOSOLUTIONS INC.: net property, plant and equipment
• EMERGENT BIOSOLUTIONS INC.: share-based compensation expense
• EMERGENT BIOSOLUTIONS INC.: operating income or loss
• EMERGENT BIOSOLUTIONS INC.: current assets
• EMERGENT BIOSOLUTIONS INC.: interest expense
• EMERGENT BIOSOLUTIONS INC.: current liabilities
• EMERGENT BIOSOLUTIONS INC.: current accounts payable
• EMERGENT BIOSOLUTIONS INC.: goodwill carrying amount
• EMERGENT BIOSOLUTIONS INC.: net finite-lived intangible assets
• EMERGENT BIOSOLUTIONS INC.: net current accounts receivable
• EMERGENT BIOSOLUTIONS INC.: common-stock repurchase payments
• EMERGENT BIOSOLUTIONS INC.: operating expenses
• EMERGENT BIOSOLUTIONS INC.: net inventory
• EMERGENT BIOSOLUTIONS INC.: gross profit
• EMERGENT BIOSOLUTIONS INC.: selling, general and administrative expense
• EMERGENT BIOSOLUTIONS INC.: research and development expense
• EMERGENT BIOSOLUTIONS INC.: common shares outstanding
• EMERGENT BIOSOLUTIONS INC.: cash including restricted cash
• EMERGENT BIOSOLUTIONS INC.: additional paid-in capital
• EMERGENT BIOSOLUTIONS INC.: accumulated other comprehensive income or loss
• EMERGENT BIOSOLUTIONS INC.: total equity including noncontrolling interests
• EMERGENT BIOSOLUTIONS INC.: operating lease liability
• EMERGENT BIOSOLUTIONS INC.: long-term debt
• EMERGENT BIOSOLUTIONS INC.: gross property, plant and equipment
• EMERGENT BIOSOLUTIONS INC.: accumulated depreciation on property, plant and equipment
• EMERGENT BIOSOLUTIONS INC.: net intangible assets excluding goodwill
• EMERGENT BIOSOLUTIONS INC.: other noncurrent assets
• EMERGENT BIOSOLUTIONS INC.: other noncurrent liabilities
• EMERGENT BIOSOLUTIONS INC.: accrued current liabilities
• EMERGENT BIOSOLUTIONS INC.: prepaid expenses and other current assets
• EMERGENT BIOSOLUTIONS INC.: current contract liabilities
• EMERGENT BIOSOLUTIONS INC.: net deferred tax assets
• EMERGENT BIOSOLUTIONS INC.: net deferred tax liabilities
• EMERGENT BIOSOLUTIONS INC.: pre-tax income or loss from continuing operations
• EMERGENT BIOSOLUTIONS INC.: profit or loss including noncontrolling interests
• EMERGENT BIOSOLUTIONS INC.: comprehensive income or loss
• EMERGENT BIOSOLUTIONS INC.: depreciation expense
• EMERGENT BIOSOLUTIONS INC.: depreciation, depletion and amortization
• EMERGENT BIOSOLUTIONS INC.: amortization of intangible assets
• EMERGENT BIOSOLUTIONS INC.: nonoperating interest expense
• EMERGENT BIOSOLUTIONS INC.: other nonoperating income or expense
• EMERGENT BIOSOLUTIONS INC.: nonoperating income or expense
• EMERGENT BIOSOLUTIONS INC.: current income tax expense or benefit
• EMERGENT BIOSOLUTIONS INC.: deferred income tax expense or benefit
• EMERGENT BIOSOLUTIONS INC.: interest paid, net
• EMERGENT BIOSOLUTIONS INC.: proceeds from issuing common stock
• EMERGENT BIOSOLUTIONS INC.: change in accounts receivable
• EMERGENT BIOSOLUTIONS INC.: change in inventories
• EMERGENT BIOSOLUTIONS INC.: change in accounts payable

Inspect the source

Entity

EMERGENT BIOSOLUTIONS INC. / CIK 0001367644

Captured

2026-09-20T07:56:38.873Z

SEC response SHA-256

fee6e59ce7e95c700b040df0c0b0b4e54545eee9eb1b957c18ae2e591985b5cb

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001367644.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))